Mitomycin‐C, methotrexate, bleomycin and cis‐diamminedichloroplatinum II in the chemotherapy of advanced squamous cancer of the head and neck

Steven E. Vogl, Harvey Lerner, Barry H. Kaplan, Fernando Camacho, James Cinberg, David Schoenfeld

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Thirty‐four patients with advanced squamous cancer of the head and neck were treated with an outpatient regimen combining mitomycin‐C, cis‐diamminedichloroplatinum (II), methotrexate and bleomycin. Five had complete remissions and 15 partial remissions, for an overall response rate of 59%. Responses were noted in 11 of 13 patients (85%) with disease above the clavicles without prior irradiation. Median duration of partial remission was four months. Response rate was independent of age, performance status, presence of distant metastases and primary site. Hematologic toxicity was substantially more severe with this program than had been observed in a prior study using the same regimen without mitomycin‐C. Since neither complete nor partial response rates, nor response durations improved with the addition of mitomycin, we conclude that it adds little to the efficacy of the other three agents.

Original languageEnglish (US)
Pages (from-to)6-9
Number of pages4
JournalCancer
Volume50
Issue number1
DOIs
StatePublished - Jul 1 1982

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Mitomycin‐C, methotrexate, bleomycin and cis‐diamminedichloroplatinum II in the chemotherapy of advanced squamous cancer of the head and neck'. Together they form a unique fingerprint.

  • Cite this